SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats

European Journal of Pharmacology

Volumn 727, Issue 1, 2014, Pages 66-74

  Yokono, Masanori ^a,d   Takasu, Toshiyuki ^a   Hayashizaki, Yuka ^a   Mitsuoka, Keisuke ^a   Kihara, Rumi ^a   Muramatsu, Yuko ^a   Miyoshi, Sousuke ^a   Tahara, Atsuo ^a   Kurosaki, Eiji ^a   Li, Qun ^b   Tomiyama, Hiroshi ^c   Sasamata, Masao ^a   Shibasaki, Masayuki ^a   Uchiyama, Yasuo ^d  

^a ASTELLAS PHARMA INC   (Japan)

^b Astellas Pharma Global Development   (Netherlands)

^c Kotobuki Pharmaceutical Co Ltd   (Japan)

^d JUNTENDO UNIVERSITY   (Japan)

Author keywords

Diabetes; High fat diet; Ipragliflozin; Obesity; Sodium glucose cotransporter 2; Urinary glucose excretion

Indexed keywords

FATTY ACID; GLUCOSE; IPRAGLIFLOZIN; SODIUM GLUCOSE COTRANSPORTER 2; ANTIDIABETIC AGENT; ANTIOBESITY AGENT; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; GLUCOSIDE; SGLT2 PROTEIN, RAT; THIOPHENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY FAT; CALORIMETRY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG MECHANISM; DUAL ENERGY X RAY ABSORPTIOMETRY; FAT MASS; FATTY ACID OXIDATION; FOOD INTAKE; LIPID DIET; LIPOLYSIS; MALE; NONHUMAN; OBESITY; PRIORITY JOURNAL; RAT; THERMOGENESIS; URINARY EXCRETION; WEIGHT REDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; DISEASE MODEL; DRUG EFFECTS; ENERGY METABOLISM; GLUCOSE BLOOD LEVEL; GLUCOSURIA; LIPID METABOLISM; METABOLISM; OXIDATION REDUCTION REACTION; PATHOPHYSIOLOGY; TIME; UPREGULATION; URINE;

ADIPOSITY; ANIMALS; ANTI-OBESITY AGENTS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; ENERGY METABOLISM; FATTY ACIDS; GLUCOSIDES; GLYCOSURIA; HYPOGLYCEMIC AGENTS; LIPID METABOLISM; OBESITY; OXIDATION-REDUCTION; RATS; SODIUM-GLUCOSE TRANSPORTER 2; THIOPHENES; TIME FACTORS; UP-REGULATION; WEIGHT LOSS;

EID: 84893682957     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2014.01.040     Document Type: Article

References (39)

1. R. Alemzadeh, M.D. Karlstad, K. Tushaus, and M. Buchholz Diazoxide enhances basal metabolic rate and fat oxidation in obese Zucker rats Metabolism 57 2008 1597 1607
2. R. Alemzadeh, and K. Tushaus Diazoxide attenuates insulin secretion and hepatic lipogenesis in Zucker diabetic fatty rats Med. Sci. Monit. 11 2005 BR439 BR448
3. J. Bolinder, O. Ljunggren, J. Kullberg, L. Johansson, J. Wilding, A.M. Langkilde, J. Sugg, and S. Parikh Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin J. Clin. Endocrinol. Metab. 97 2012 1020 1031
4. S. Colagiuri Diabesity: therapeutic options Diabetes Obes. Metab. 12 2010 463 473
5. A.A. da Silva, J. do Carmo, J. Dubinion, and J.E. Hall The role of the sympathetic nervous system in obesity-related hypertension Curr. Hypertens. Rep. 11 2009 206 211
6. J.P. Despres Body fat distribution and risk of cardiovascular disease: an update Circulation 126 2012 1301 1313
7. J.J. Devenny, H.E. Godonis, S.J. Harvey, S. Rooney, M.J. Cullen, and M.A. Pelleymounter Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats Obesity (Silver Spring) 20 2012 1645 1652
8. R.P. Eaton, and D.S. Schade The effect of diazoxide-induced hormonal secretion on plasma triglyceride concentration in the rat Diabetologia 18 1980 301 306 (Pubitemid 10134425)
9. R.H. Eckel, S.E. Kahn, E. Ferrannini, A.B. Goldfine, D.M. Nathan, M.W. Schwartz, R.J. Smith, and S.R. Smith Obesity and type 2 diabetes: what can be unified and what needs to be individualized? Diabetes Care 34 2011 1424 1430
10. M.J.T. Engelbregt, A.M. Tromp, A. van Lingen, P. Lips, and C. Popp-Snijders Validation of whole body DXA in young and adult rats Horm. Res. 51 Suppl. 2 1999 P428 (abstract)
11. E. Ferrannini, S.J. Ramos, A. Salsali, W.H. Tang, and J.F. List Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise a randomized, double-blind, placebo-controlled, phase 3 trial Diabetes Care 33 2010 2217 2224
12. E. Ferrannini, L. Seman, E. Seewaldt-Becker, S. Hantel, S. Pinnetti, and H.J. Woerle A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes Diabetes Obes. Metab. 15 2013 721 728
13. V.A. Fonseca, E. Ferrannini, J.P. Wilding, W. Wilpshaar, P. Dhanjal, G. Ball, and S. Klasen Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus J. Diabetes Complications 27 2013 268 273
14. M.I. Gurr Animal models for the study of energy balance Proc. Nutr. Soc. 39 1980 219 225
15. J.J. Hillebrand, W. Langhans, and N. Geary Validation of computed tomographic estimates of intra-abdominal and subcutaneous adipose tissue in rats and mice Obesity (Silver Spring) 18 2010 848 853
16. M. Imamura, K. Nakanishi, T. Suzuki, K. Ikegai, R. Shiraki, T. Ogiyama, T. Murakami, E. Kurosaki, A. Noda, Y. Kobayashi, M. Yokota, T. Koide, K. Kosakai, Y. Ohkura, M. Takeuchi, H. Tomiyama, and M. Ohta Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus Bioorg. Med. Chem. 20 2012 3263 3279
17. N. Inagaki, K. Kondo, T. Yoshinari, N. Maruyama, Y. Susuta, and H. Kuki Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study Diabetes Obes. Metab. 15 2013 1136 1145
18. M.V. Jensen, J.W. Joseph, S.M. Ronnebaum, S.C. Burgess, A.D. Sherry, and C.B. Newgard Metabolic cycling in control of glucose-stimulated insulin secretion Am. J. Physiol. Endocrinol. Metab. 295 2008 E1287 1297
19. M.J. Jurczak, H.Y. Lee, A.L. Birkenfeld, F.R. Jornayvaz, D.W. Frederick, R.L. Pongratz, X. Zhao, G.W. Moeckel, V.T. Samuel, J.M. Whaley, G.I. Shulman, and R.G. Kibbey SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function Diabetes 60 2011 890 898
20. A. Kashiwagi, Y. Takinami, K. Kazuta, S. Yoshida, A. Utsuno, and I. Nagase Irpagliflozin improved glycemia control with additional benefits of reductions of body weight and blood pressure in Japanese patients with type 2 diabetes mellitus: BRIGHTEN Study Diabetogogia 54 Suppl. 1 2011 149 (abstract)
21. A. Kashiwagi, A. Utsuno, K. Kazuta, S. Yoshida, and S. Kageyama ASP1941, a novel, selective SGLT2 inhibitor, was effective and safe in Japanese healthy volunteers and patients with type 2 diabetes Diabetes 59 Suppl. 1 2010 A21 (abstract)
22. Y. Liang, K. Arakawa, K. Ueta, Y. Matsushita, C. Kuriyama, T. Martin, F. Du, Y. Liu, J. Xu, B. Conway, J. Conway, D. Polidori, K. Ways, and K. Demarest Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models PLoS One 7 2012 e30555
23. G. Livesey, and M. Elia Estimation of energy expenditure, net carbohydrate utilization, and net fat oxidation and synthesis by indirect calorimetry: evaluation of errors with special reference to the detailed composition of fuels Am. J. Clin. Nutr. 47 1988 608 628
24. Y.K. Luu, S. Lublinsky, E. Ozcivici, E. Capilla, J.E. Pessin, C.T. Rubin, and S. Judex In vivo quantification of subcutaneous and visceral adiposity by micro-computed tomography in a small animal model Med. Eng. Phys. 31 2009 34 41
25. N. Marty, M. Dallaporta, and B. Thorens Brain glucose sensing, counterregulation, and energy homeostasis Physiology (Bethesda) 22 2007 241 251
26. M.A. Osundiji, D.D. Lam, J. Shaw, C.Y. Yueh, S.P. Markkula, P. Hurst, C. Colliva, A. Roda, L.K. Heisler, and M.L. Evans Brain glucose sensors play a significant role in the regulation of pancreatic glucose-stimulated insulin secretion Diabetes 61 2012 321 328
27. I. Sabolic, I. Vrhovac, D.B. Eror, M. Gerasimova, M. Rose, D. Breljak, M. Ljubojevic, H. Brzica, A. Sebastiani, S.C. Thal, C. Sauvant, H. Kipp, V. Vallon, and H. Koepsell Expression of Na+-d-glucose cotransporter SGLT2 in rodents is kidney-specific and exhibits sex and species differences Am. J. Physiol. Cell Physiol. 302 2012 C1174 C1188
28. S.L. Schwartz, B. Akinlade, S. Klasen, D. Kowalski, W. Zhang, and W. Wilpshaar Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus Diabetes Technol. Ther. 13 2011 1219 1227
29. A. Tahara, E. Kurosaki, M. Yokono, D. Yamajuku, R. Kihara, Y. Hayashizaki, T. Takasu, M. Imamura, Q. Li, H. Tomiyama, Y. Kobayashi, A. Noda, M. Sasamata, and M. Shibasaki Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice Eur. J. Pharmacol. 715 2013 246 255
30. A. Tahara, E. Kurosaki, M. Yokono, D. Yamajuku, R. Kihara, Y. Hayashizaki, T. Takasu, M. Imamura, L. Qun, H. Tomiyama, Y. Kobayashi, A. Noda, M. Sasamata, and M. Shibasaki Antidiabetic effects of SGLT2-selective inhibitor ipragliflozin in streptozotocin-nicotinamide-induced mildly diabetic mice J. Pharmacol. Sci. 120 2012 36 44
31. A. Tahara, E. Kurosaki, M. Yokono, D. Yamajuku, R. Kihara, Y. Hayashizaki, T. Takasu, M. Imamura, L. Qun, H. Tomiyama, Y. Kobayashi, A. Noda, M. Sasamata, and M. Shibasaki Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo Naunyn-Schmiedeberg×s Arch. Pharmacol. 385 2012 423 436
32. P. Trayhurn, C.A. Drevon, and J. Eckel Secreted proteins from adipose tissue and skeletal muscle - adipokines, myokines and adipose/muscle cross-talk Arch. Physiol. Biochem. 117 2011 47 56
33. R.H. Unger Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications Diabetes 44 1995 863 870
34. V. Vallon, K.A. Platt, R. Cunard, J. Schroth, J. Whaley, S.C. Thomson, H. Koepsell, and T. Rieg SGLT2 mediates glucose reabsorption in the early proximal tubule J. Am. Soc. Nephrol. 22 2011 104 112
35. L.P. van den Heuvel, K. Assink, M. Willemsen, and L. Monnens Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2) Hum. Genet. 111 2002 544 547 (Pubitemid 36075086)
36. R.G. Wells, A.M. Pajor, Y. Kanai, E. Turk, E.M. Wright, and M.A. Hediger Cloning of a human kidney cDNA with similarity to the sodium-glucose cotransporter Am. J. Physiol. 263 1992 F459 465
37. J.P. Wilding, E. Ferrannini, V.A. Fonseca, W. Wilpshaar, P. Dhanjal, and A. Houzer Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study Diabetes Obes. Metab. 15 2013 403 409
38. E.M. Wright, B.A. Hirayama, and D.F. Loo Active sugar transport in health and disease J. Intern. Med. 261 2007 32 43 (Pubitemid 46046470)
39. L. Zhang, Y. Feng, J. List, S. Kasichayanula, and M. Pfister Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight Diabetes Obes. Metab. 12 2010 510 516